TICKERNERD
Menu
NNVCNNVCHealthcare · Biotechnology

NNVC Stock Forecast: NanoViricides, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$1.33
+1.53% on the day

The 2 Wall Street analysts covering NanoViricides, Inc. hold a median 12-month price target of $6 — +351.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$33.9M
Ticker Nerd rank
58 / 100
Median analyst target
$6.00
Analysts covering
2
Total return, dividends reinvested
1W
−3.6%
1M
−16.9%
YTD
+17.7%
1Y
−2.9%
From 52W high
−34.5%
From 52W low
+56.5%
$0.85
$2.03
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NNVC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NanoViricides, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
58 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
85
Growth
76
Accruals
68
Volatility
61
Value
56
Momentum
54
Revisions
36
Quality
36
Issuance
33

Size (85): Smaller than most of the companies we track.

Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NNVC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NNVC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26NNVCHigh $6.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $6.00Median $6.00High $6.00

The green dot is the last close — the median target sits +351.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
6 July 2026Noble Capital MarketsInitiatesOutperform—
7 May 2024EF HuttonReiteratesBuy—
16 Feb 2024EF HuttonReiteratesBuy—
1 June 2023EF HuttonAssumesBuy$5.25
18 Apr 2023EF HuttonReiteratesBuy—
28 Feb 2023EF HuttonMaintainsBuy$8.50 → $5.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NNVC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NNVC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

NanoViricides, Inc. (NNVC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.1×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
3.1×

Cheaper than 34% of US stocks

EV / EBITDA
−3.4×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−90.0%

Higher than 14% of US stocks

Return on assets
−50.5%

Higher than 8% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NNVC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NNVCNanoViricides, Inc.$33.9M
58
QNCXQuince Therapeutics, Inc.$33.2M
25
ATNMActinium Pharmaceuticals, Inc.$34.5M
69
BCTXBriaCell Therapeutics Corp.$35.1M
7
LITSLite Strategy, Inc.$35.3M
28
IGCIGC Pharma, Inc.$31.8M
6
ESLAEstrella Immunopharma, Inc.$30.9M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NanoViricides, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NNVC news & analysis

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Accesswire · 18 Aug 2026positive

NanoViricides announced that its Phase II clinical trial of NV-387 Oral Gummies as a treatment for the Bundibugyo ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo. Professor Patrick Katoto has been appointed as principal investigator to lead the trial.

Why it matters — This marks progress for NanoViricides' lead antiviral candidate NV-387 moving into a Phase II trial against an active Ebola outbreak, a significant clinical milestone for the company.

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Accesswire · 10 Aug 2026positive

NanoViricides announced that it has received regulatory approval from the DRC's local agency ACOREP to begin a Phase II clinical trial of its NV-387 Oral Gummies as a treatment for Bundibugyo Ebolavirus and other Ebola viruses. The company has retained Om Sai Clinical Research Private Limited as the CRO for this trial in the DRC.

Why it matters — A NNVC watcher would care because this marks regulatory approval to advance NV-387 into a Phase II Ebola trial amid the current outbreak in the DRC.

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Accesswire · 28 July 2026positive

NanoViricides has filed an application with the DR Congo regulatory agency ACOREP to begin a Phase II clinical trial of NV-387 Oral Gummies as a treatment for the Bundibugyo Ebolavirus, and says it has raised the necessary financing to support the trial.

Why it matters — A NNVC watcher would care because this marks a key regulatory milestone for the company's lead antiviral candidate NV-387 advancing toward a Phase II trial in an active Ebola outbreak setting.

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

Accesswire · 24 July 2026neutral

NanoViricides announced a registered direct offering raising approximately US$3.8 million through the sale of common stock and warrants to a single institutional investor.

Why it matters — The offering provides additional capital to the company but will result in dilution for existing shareholders.

FAQ

Frequently asked questions about NNVC stock

What is the NNVC stock price forecast for 2026-2027?

The 2 Wall Street analysts covering NanoViricides, Inc. have a median 12-month price target of $6, with estimates ranging from $6 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NNVC stock a buy right now?

Of the 2 analysts covering NanoViricides, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NanoViricides, Inc. 58 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NNVC?

As at 22 Aug 2026, NanoViricides, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (85 of 100).

Will NNVC stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +351.1% from the last close, and Ticker Nerd's factor model ranks NanoViricides, Inc. 58 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NNVC stock forecast for 2030?

No analyst covering NanoViricides, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NNVC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.

How has NNVC stock performed over the past year?

NanoViricides, Inc. returned -2.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NanoViricides, Inc. do?

Nanoviricides Inc. is a pioneering biotechnology company that focuses on the development of therapeutics to combat viral infections using nanotechnology.

What is the latest news on NNVC?

The most recent item we track (Accesswire, 18 Aug 2026): "The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon". NanoViricides announced that its Phase II clinical trial of NV-387 Oral Gummies as a treatment for the Bundibugyo ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo. Professor Patrick Katoto has been appointed as principal investigator to lead the trial.

Company

About NanoViricides, Inc.

Nanoviricides Inc. is a pioneering biotechnology company that focuses on the development of therapeutics to combat viral infections using nanotechnology. The company is dedicated to creating antiviral nanomedicine known as "nanoviricides," which are designed to specifically attack and neutralize virus particles. This innovative approach allows Nanoviricides Inc. to target a wide range of viruses effectively and with precision. The central aim of Nanoviricides Inc. is to address unmet medical needs, particularly in treating viral diseases for which there are limited or no effective treatments available. The biotechnology sector heavily influences its operations, placing it at the cutting edge of medical and scientific advancement. Its products have the potential to serve critical roles in healthcare, particularly in infectious disease control. Nanoviricides Inc.'s work is significant within the pharmaceutical and healthcare industries as it embodies the growing trend towards precision medicine and personalized healthcare solutions. By leveraging nanotechnology, Nanoviricides Inc. aims to make substantial contributions to public health and play a vital role in future pandemics and viral outbreak responses.

CEO Dr. Anil R. Diwan Ph.D. · 7 employees · United States · https://www.nanoviricides.com